Genmab Yönetim

Yönetim kriter kontrolleri 2/4

Genmab CEO'su Jan G.J. de Winkel, Jun2010 tarihinde atandı, in görev süresi 14.67 yıldır. in toplam yıllık tazminatı DKK 54.80M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.7% maaş ve 82.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.99% ine doğrudan sahiptir ve bu hisseler DKK 998.22M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.3 yıl ve 7.9 yıldır.

Anahtar bilgiler

Jan G.J. de Winkel

İcra Kurulu Başkanı

DKK 54.8m

Toplam tazminat

CEO maaş yüzdesi	17.7%
CEO görev süresi	14.7yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	7.3yrs
Yönetim Kurulu ortalama görev süresi	7.9yrs

Son yönetim güncellemeleri

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

CEO Tazminat Analizi

Jan G.J. de Winkel'un ücretlendirmesi Genmab'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	DKK 55m	DKK 10m	DKK 8b
Sep 30 2024	n/a	n/a	DKK 5b
Jun 30 2024	n/a	n/a	DKK 6b
Mar 31 2024	n/a	n/a	DKK 5b
Dec 31 2023	DKK 44m	DKK 9m	DKK 4b
Sep 30 2023	n/a	n/a	DKK 4b
Jun 30 2023	n/a	n/a	DKK 5b
Mar 31 2023	n/a	n/a	DKK 5b
Dec 31 2022	DKK 42m	DKK 9m	DKK 5b
Sep 30 2022	n/a	n/a	DKK 6b
Jun 30 2022	n/a	n/a	DKK 4b
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b

Tazminat ve Piyasa: Jan G.J. 'nin toplam tazminatı ($USD 7.68M ), Danish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 3.89M ).

Tazminat ve Kazançlar: Jan G.J. 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Jan G.J. de Winkel (63 yo)

14.7yrs

Görev süresi

DKK 54,800,000

Tazminat

Dr. Jan G.J. van de Winkel, Ph.D. was Independent Director of HOOKIPA Pharma Inc. from 2023 until August 30, 2024 and served as Chairman of the Board since 2024 August 30, 2024. Dr. Winkel served as a Memb...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jan G.J. de Winkel	Co-Founder	14.7yrs	DKK 54.80m	0.99% DKK 998.2m
Anthony Pagano	Executive VP & CFO	4.9yrs	DKK 24.00m	0.011% DKK 11.1m
Rayne Waller	Executive VP & Chief Technical Operations Officer	less than a year	DKK 5.88m	Veri yok
Birgitte Stephensen	Executive VP & Chief Legal Officer	15.1yrs	DKK 13.20m	Veri yok
Christopher Cozic	Executive VP & Chief People Officer	7.3yrs	DKK 16.60m	Veri yok
Martine van Vugt	Executive VP & Chief Strategy Officer	11.1yrs	DKK 10.90m	Veri yok
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	DKK 1.40m	0.00061% DKK 613.6k
Judith Klimovsky	Executive VP & Chief Development Officer	8yrs	DKK 27.90m	0.017% DKK 17.1m
Tahamtan Ahmadi	Executive VP	3.9yrs	DKK 25.80m	0.0076% DKK 7.7m
Mijke Zachariasse	Senior Director	no data	DKK 1.60m	0.0012% DKK 1.2m
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	DKK 1.40m	0.00013% DKK 130.8k
Brad Bailey	Executive VP & Chief Commercial Officer	less than a year	DKK 16.56m	Veri yok

7.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: GMAB 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	3.1yrs	DKK 1.40m	0.00061% DKK 613.6k
Mijke Zachariasse	Senior Director	5.9yrs	DKK 1.60m	0.0012% DKK 1.2m
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	3.1yrs	DKK 1.40m	0.00013% DKK 130.8k
Anders Pedersen	Non-Independent Director	21.3yrs	DKK 2.10m	0.012% DKK 11.9m
Elizabeth O'Farrell	Independent Director	2.9yrs	DKK 2.60m	0.0011% DKK 1.1m
Deirdre Connelly	Independent Chairman of the Board	7.9yrs	DKK 3.30m	0.0098% DKK 9.8m
Rolf Hoffmann	Independent Director	7.9yrs	DKK 2.00m	0.0056% DKK 5.7m
Pernille Erenbjerg	Independent Deputy Chairman	10.1yrs	DKK 2.60m	0.0082% DKK 8.2m
Paolo Paoletti	Independent Director	10.1yrs	DKK 1.90m	0.0037% DKK 3.7m

7.9yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GMAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/21 06:15
Gün Sonu Hisse Fiyatı	2025/02/21 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Genmab A/S 45 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Andrew Carlsen	ABG Sundal Collier
Armelle Moulin	AlphaValue
Emily Field	Barclays

Genmab Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genmab A/S, Annual General Meeting, Mar 12, 2025

Insufficient new directors

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces Executive Changes

Recent updates

Consensus EPS estimates increase by 16%

Genmab A/S Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next

Genmab A/S, Annual General Meeting, Mar 12, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Provides Revenue Guidance for 2025

Insufficient new directors

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş